JINXIN FERT.GRP HD-00001 risk profile
58 Elevated one input has moved against it
Measured 1 September 2026 from 3NX's filed statements. Recomputed nightly.
58 (Elevated), driven by Leverage and coverage at 96, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 64 | Stretched | Easing | Average daily turnover — $26 |
| Operating pressure | 59 | Elevated | Worsening | Costs outgrowing revenue — +9.3 percentage points |
| Cash conversion | 30 | Normal | Worsening | Capital spending against operating cash — 0.45x |
| Leverage and coverage | 96 | Acute | Worsening | Net debt to EBITDA |
| Competitive position | 51 | Elevated | Stable | Revenue-growth gap against peers — -17.6 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for JINXIN FERT.GRP HD-00001